This report helps to identify factors, which will be the driving force behind
the U.S. vaccine market and sub-markets in the next six years. The report
provides extensive analysis of the US vaccine industry, current market trends,
industry drivers and challenges for better understanding of the U.S.vaccine
market structure. The report has segregated the U.S. vaccine industry in terms
of product type. Annual estimates and forecasts are provided for the period
2012 through 2018 in terms of in USD million.
The report helps in providing a comprehensive overview for
Market forces that are driving and restraining the growth of the industry
Opportunities for the application segments
Up-to-date analysis of the latest trends in the industry
Acumen into the size and shape of the market growth
Detailed outlook of the market and its future
Reasons for buying this report
Forward-looking perspective on a category, market or issue affecting the
industry growth
Six year forecast assess how the market is predicted to grow and segmental
behavior
Understand the competitive environment, the leading players and segments
in the market
Clear understanding about the key product segments and identification of
most robust product segment will help in ensuring strong returns
Pin-point analysis of changing dynamics of competition keeps you ahead of
the competitors
Make more informed business decisions from insightful and in-depth
analysis of the technical and commercial strength of U.S. vaccine Market
andits performance
Observe the chronological sales performance of a U.S. vaccine Marketin
major regional markets
Obtain sales forecast for currently marketed U.S. vaccine Market
application for 2012 - 2018 for the U.S. market
Major Segments Analyzed
Human vaccine
Pediatric vaccines
Adult &adolescent vaccine
Other human vaccine
Animal vaccine
Livestock vaccine
Bovine vaccine
Porcine vaccine
Ovine vaccine
Companion animal vaccine
Feline vaccine
Canine vaccine
Equine vaccine
Other animal vaccine
Methodology
For the research report, we conducted in-depth interviews and discussions with
a wide range of key industry participants and opinion leaders. Primary
research represents the bulk of our research efforts, supplemented by
extensive secondary research. We reviewed the key players' product literature,
annual reports, press releases and relevant documents for competitive analysis
and market understanding. Secondary research also includes a search of recent
trade journals, technical writing, internet sources, and statistical data from
government websites, trade associations and agencies. This approach has proven
to be the most reliable, effective and successful approach for obtaining
precise market data, capturing industry participants' insights, and
recognizing business opportunities.
Table of Contents
Table of Contents
CHAPTER 1 INTRODUCTION
1.1 REPORT DESCRIPTION
1.2 METHODOLOGY
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 U.S. VACCINE MARKET, 2012 - 2018
3.1 MARKET OVERVIEW
3.2 VACCINE MARKET CHARACTERISTICS
3.3 LAWS AND REGULATIONS
3.3.1 VACCINE APPROVAL PROCESS
3.4 U.S. VACCINE MARKET ESTIMATE AND FORECAST, 2012 - 2018
3.4.1 MARKET SHARE BY VACCINE TYPE
3.5 LIST OF COMPANIES SUPPLYING VACCINES IN THE U.S.
3.6 VACCINE PRICING
3.6.1 PRICES FOR VACCINES CONTAINING THIMEROSAL AS A PRESERVATIVE
3.6.2 PRICES OF VACCINES FREE OF PRESERVATIVES:
3.7 MARKET DYNAMICS
3.7.1 DRIVERS
3.7.1.1 Rise in incidences of viral infection driving the growth of
vaccine market in the U.S.
3.7.1.2 Biotechnology research enabling synthesis of new vaccines to
target complex human diseases driving the vaccine market
3.7.1.3 Government recommendation for adult and adolescent
immunization will boost the growth of Vaccine market in U.S.
3.7.1.4 Rise in infectious diseases in animals driving the market
3.7.2 RESTRAINTS
3.7.2.1 Cost of refrigeration
3.7.2.2 Short functional shelf life of certain vaccines will have
negative impact on the market growth
3.7.3 OPPORTUNITIES
3.7.3.1 Huge product pipeline of the multinational firms will act as
an opportunity for future growth
3.8 IMPACT ANALYSIS OF DRIVERS
3.9 IMPACT ANALYSIS OF RESTRAINTS
3.10 PORTER'S FIVE FORCE ANALYSIS
3.10.1 BARGAINING POWER OF SUPPLIER
3.10.2 BARGAINING POWER OF BUYER
3.10.3 RIVALRY AMONG EXISTING COMPETITORS
3.10.4 THREAT OF NEW ENTRANTS
3.10.5 THREAT OF SUBSTITUTE
CHAPTER 4 U.S. VACCINE MARKET BY PRODUCT TYPE
4.1 HUMAN VACCINE
4.1.1 MARKET ANALYSIS, SIZE AND FORECAST
4.1.2 MARKET ATTRACTIVENESS ANALYSIS FOR HUMAN VACCINE MARKET
4.1.3 PEDIATRIC VACCINES
4.1.3.1 Market Analysis, Size and Forecast
4.1.3.2 Pediatric vaccine price list
4.1.3.3 Pediatric Influenza Vaccine price list
4.1.3.4 HaemophilusInfluenzae Type B
4.1.3.4.1 Hib Pricing
4.1.3.5 Hepatitis A
4.1.3.5.1 HAV Pricing
4.1.3.6 Hepatitis B
4.1.3.6.1 Hepatitis B Pricing
4.1.4 ADULT & ADOLESCENT VACCINES
4.1.4.1 Market Analysis, Size and Forecast
4.1.4.2 Adult vaccine price list
4.1.4.3 Adult Influenza Vaccine price list
4.1.5 OTHER HUMAN VACCINES
4.1.5.1 Market Analysis, Size and Forecast
4.2 ANIMAL VACCINE
4.2.1 MARKET ANALYSIS, SIZE AND FORECAST
4.2.2 MARKET ATTRACTIVENESS ANALYSIS FOR ANIMAL VACCINE
4.2.3 LIVESTOCK VACCINES
4.2.3.1 Market Analysis, Size and Forecast
4.2.3.2 Bovine Vaccines
4.2.3.2.1 Market Analysis, Size and Forecast
4.2.3.3 Porcine Vaccines
4.2.3.3.1 Market Analysis, Size and Forecast
4.2.3.4 Ovine Vaccines
4.2.3.4.1 Market Analysis, Size and Forecast
4.2.4 COMPANION ANIMAL VACCINES
4.2.4.1 Market Analysis, Size and Forecast
4.2.4.2 Feline Vaccines
4.2.4.2.1 Market Analysis, Size and Forecast
4.2.4.3 Canine Vaccines
4.2.4.3.1 Market Analysis, Size and Forecast
4.2.4.4 Equine Vaccines
4.2.4.4.1 Market Analysis, Size and Forecast
4.2.5 OTHER ANIMAL VACCINES
4.2.5.1 Market Analysis, Size and Forecast
CHAPTER 5 COMPETITIVE LANDSCAPE
5.1 MARKET SHARE ANALYSIS
5.2 COMPETITIVE ANALYSIS FOR KEY MARKET PLAYERS
CHAPTER 6 COMPANY PROFILE
6.1 SANOFI-AVENTIS
6.1.1 COMPANY OVERVIEW
6.1.2 FINANCIAL OVERVIEW
6.1.3 SWOT ANALYSIS
6.1.1 RECENT DEVELOPMENT
6.2 GLAXOSMITHKLINE
6.2.1 COMPANY OVERVIEW
6.2.2 FINANCIAL OVERVIEW:
6.2.3 SEGMENT OVERVIEW
6.2.4 SWOT ANALYSIS
6.2.5 RECENT DEVELOPMENTS
6.3 MERCK & COMPANY INCORPORATED
6.3.1 COMPANY OVERVIEW
6.3.2 FINANCIAL OVERVIEW:
6.3.1 RECENT DEVELOPMENT
6.4 PFIZER INCORPORATED
6.4.1 COMPANY OVERVIEW
6.4.2 FINANCIAL OVERVIEW
6.4.3 RECENT DEVELOPMENT
6.5 ASTRAZENECA PLC
6.5.1 COMPANY OVERVIEW
6.5.2 FINANCIAL OVERVIEW:
6.5.3 RECENT DEVELOPMENT
6.6 NOVARTIS AG
6.6.1 COMPANY OVERVIEW
6.6.2 FINANCIAL OVERVIEW:
6.6.3 SWOT ANALYSIS
6.6.1 RECENT DEVELOPMENT
6.7 BOEHRINGER
6.7.1 COMPANY OVERVIEW
6.7.2 NET SALES BY BUSINESS
6.7.3 SWOT ANALYSIS
6.7.4 RECENT DEVELOPMENT
LIST OF FIGURES
FIG. 1 U.S. VACCINE MARKET REVENUE, BY PRODUCT TYPE, 2012 - 2018, (USD
MILLION)
TABLE 1 ACTS AND REGULATIONS PERTINENT TO VACCINE DEVELOPMENT
TABLE 2 SELECT FDA AND ICH GUIDANCE DOCUMENTS RELEVANT TO VACCINE
DEVELOPMENT
TABLE 3 LOT-RELEASE TESTING GUIDLINES
TABLE 1 U.S. VACCINE MARKET REVENUE, BY PRODUCT TYPE, 2012 - 2018, (USD
MILLION)
TABLE 2 GSK PRODUCT PIPELINE
TABLE 3 U.S. HUMAN VACCINE MARKET REVENUE, BY PRODUCT TYPE 2012 - 2018
(USD MILLION)
TABLE 4 U.S. ANIMAL VACCINE MARKET REVENUE, BY PRODUCT TYPE 2012 - 2018
(USD MILLION)
TABLE 5 U.S. LIVESTOCK VACCINES MARKET REVENUE, BY PRODUCT TYPE 2012 -
2018 (USD MILLION)
TABLE 6 U.S. COMPANION ANIMAL VACCINES MARKET REVENUE, BY PRODUCT TYPE
2012- 2018 (USD MILLION)
U.S. Vaccine Market - U.S. Industry Analysis, Size, Share, Growth, And Forecast, 2012 - 2018 published by Transparency Market Research in September 13, 2012. This report consists of 71 Pages and the price starts from US $ 2795.
